Today: 6 February 2026
Subscribe
Browse Category

Medical Technology News 23 January 2026 - 6 February 2026

Haemonetics stock slides 7% as revenue dip and hospital softness blunt raised outlook

Haemonetics stock slides 7% as revenue dip and hospital softness blunt raised outlook

Haemonetics shares dropped 7% Friday to $60.46 despite the company raising its full-year profit and cash flow outlook. Third-quarter revenue fell 2.7% to $339 million, while adjusted EPS rose to $1.31. Interventional technology revenue declined 12%, offsetting a 3% gain in plasma. Citigroup cut its price target to $75.
6 February 2026
·····
Boston Scientific stock price steadies after historic plunge as investors zero in on heart-rhythm outlook

Boston Scientific stock price steadies after historic plunge as investors zero in on heart-rhythm outlook

Boston Scientific shares slipped 0.2% to $77.49 in late-morning trading Friday, lagging a broader market rally. The stock remains under pressure after its electrophysiology segment missed sales estimates in the fourth quarter, triggering its steepest drop in over 25 years. Investors are watching for signs management can meet first-quarter growth targets. Trading volume stayed elevated as analysts revised forecasts.
6 February 2026
····
Boston Scientific stock rebounds after earnings shock as analysts cut targets on EP worries

Boston Scientific stock rebounds after earnings shock as analysts cut targets on EP worries

New York, February 5, 2026, 18:10 EST — After-hours trading Boston Scientific shares climbed 2.8% Thursday, closing at $77.64. Trading volume hit roughly 38.3 million shares. The stock found some footing following a sharp drop sparked by earnings that pushed investors to revise their outlook fast. The focus has shifted from the headline beat to concerns over whether the company’s growth drivers are starting to falter. The stock tumbled as much as 17% on Wednesday, marking its sharpest one-day drop in over 25 years, after the company reported weaker-than-expected Q4 sales in its electrophysiology segment. That unit recorded $890 million
6 February 2026
·····
Why Johnson & Johnson stock is up today: new Varipulse Plus update puts AFib data back in play

Why Johnson & Johnson stock is up today: new Varipulse Plus update puts AFib data back in play

New York, Feb 3, 2026, 13:08 EST — Regular session Johnson & Johnson (JNJ.N) shares climbed roughly 1.4% Tuesday following an initial drop, boosted by the company’s newest update on its heart device. The stock traded at $233.87 in the afternoon, bouncing between $230.00 and $235.24 earlier in the session. This shift is crucial as investors seek confirmation that Johnson & Johnson’s MedTech division can keep expanding its growth trajectory without faltering on execution. Cardiac devices tend to be sticky—hospitals rarely switch once they settle on a standard, given the high costs and hassle involved. Trading desks are keyed in
3 February 2026
·····
Intuitive Surgical stock slips into the weekend: ISRG traders eye insider sale, tariffs, and what comes next

Intuitive Surgical stock slips into the weekend: ISRG traders eye insider sale, tariffs, and what comes next

New York, Feb 1, 2026, 17:25 EST — The market has closed. Intuitive Surgical shares edged down 0.7% on Friday, closing at $504.22 on the Nasdaq. Investors are cautious heading into Monday following a filing that revealed the company’s chief medical officer offloaded stock. The price fluctuated between $501.44 and $510.75, with roughly 1.7 million shares traded. (SEC) Why it matters now: the stock remains reactive to the company’s 2026 outlook, where management projects slower growth in a crucial metric — procedures, or the number of surgeries performed with da Vinci systems. This metric drives repeat sales of instruments and
1 February 2026
·····
Intuitive Surgical stock in focus after FDA clears da Vinci 5 for heart procedures

Intuitive Surgical stock in focus after FDA clears da Vinci 5 for heart procedures

New York, January 26, 2026, 21:24 EST — Market closed Shares of Intuitive Surgical climbed to $528.81 on Nasdaq, marking roughly a 1% gain from the prior close. The uptick followed news that the U.S. Food and Drug Administration approved its da Vinci 5 surgical robot for select cardiac procedures. (Barchart.com) The clearance arrives as investors seek new growth avenues beyond the core da Vinci system. Intuitive reported last week that global procedure volumes jumped roughly 18% in Q4. The company projects da Vinci procedure growth to slow to about 13% to 15% in 2026, down from 2025 levels. (SEC)
27 January 2026
···
ISRG stock edges up after Intuitive Surgical wins FDA clearance for da Vinci 5 heart procedures

ISRG stock edges up after Intuitive Surgical wins FDA clearance for da Vinci 5 heart procedures

New York, Jan 26, 2026, 2:04 PM EST — Regular session Intuitive Surgical shares climbed roughly 1% Monday following U.S. regulatory clearance of its newest da Vinci 5 robot for select heart procedures, providing a new boost after the stock’s swings post-earnings last week. Cardiac surgery is a major, high-risk field that’s been slow to adopt minimally invasive methods. Intuitive is betting that the da Vinci 5 clearance will expand the range of procedures performed with its systems, boosting ongoing sales of instruments and accessories. This comes as investors weigh whether fresh indications and system placements can maintain growth, even
26 January 2026
····
Intuitive Surgical stock price: what to watch Monday after ISRG’s 2026 da Vinci outlook and tariffs hit focus

Intuitive Surgical stock price: what to watch Monday after ISRG’s 2026 da Vinci outlook and tariffs hit focus

New York, Jan 25, 2026, 15:28 EST — Market closed. Intuitive Surgical (ISRG) shares closed Friday at $523.99, slipping roughly 0.4% following the company’s cautious growth forecast for 2026. U.S. markets will resume trading on Monday. The main question now: Is Intuitive’s forecast for procedure growth cautious, or a sign that hospital demand is genuinely slowing? “Procedure growth” measures how many surgeries use its systems, a key figure since it fuels recurring sales of instruments, accessories, and service. Leerink Partners’ Mike Kratky said the guidance “leaves room for upside,” boosting his price target to $622 from $600, while maintaining an
25 January 2026
·····
Intuitive Surgical stock slips into weekend after earnings beat, with tariffs and 2026 outlook in focus

Intuitive Surgical stock slips into weekend after earnings beat, with tariffs and 2026 outlook in focus

New York, Jan 24, 2026, 17:23 EST — The market has closed. Intuitive Surgical (ISRG.O) shares ended Friday 0.4% lower at $523.99, with investors digesting a quarterly beat offset by a weaker growth forecast and higher tariff expenses. U.S. markets remain closed until Monday, leaving the stock heading into the new week shadowed by two key uncertainties: the pace at which procedure growth slows, and the extent to which tariffs will erode margins. That’s key since “procedure growth”—the count of surgeries done with Intuitive’s robots—directly boosts demand for the single-use instruments and accessories that form a large portion of repeat
25 January 2026
·····
Intuitive Surgical stock slips as 2026 growth outlook cools — what to watch before Monday

Intuitive Surgical stock slips as 2026 growth outlook cools — what to watch before Monday

New York, January 23, 2026, 20:18 EST — Market closed Intuitive Surgical shares dipped 0.35% to end Friday at $523.99, as investors digested the company’s 2026 forecast following its recent quarterly report. (MarketScreener) Why it matters now: procedure growth — the tally of surgeries performed with Intuitive’s systems — is the key demand indicator investors track. It fuels recurring sales of instruments, accessories, and service, extending well beyond just initial system installations. The 2026 guidance now stands as the key focus heading into next week. The company also highlighted tariffs as a threat to margins, warning that those cost fluctuations
24 January 2026
·····
Boston Scientific stock (BSX) climbs as heart-rhythm rivalry and deal risk stay in play

Boston Scientific stock (BSX) climbs as heart-rhythm rivalry and deal risk stay in play

New York, January 23, 2026, 15:50 (EST) — Regular session Shares of Boston Scientific Corp edged up roughly 1% to $92.20 in late afternoon trading on Friday, fluctuating earlier between $90.89 and $92.33. Investors are being nudged to watch pulsed-field ablation (PFA), a newer technique for treating atrial fibrillation—an irregular heartbeat linked to higher stroke risk. PFA delivers short electrical pulses to target faulty tissue, sparking a fierce battle for market dominance. This is critical now since the winners in PFA can outpace the broader medical-device market in growth, while the losers risk declines in procedure volumes and pricing. Boston
23 January 2026
····
Intuitive Surgical stock price dips as 2026 da Vinci outlook cools after Q4 beat (ISRG)

Intuitive Surgical stock price dips as 2026 da Vinci outlook cools after Q4 beat (ISRG)

NEW YORK, Jan 23, 2026, 13:25 EST — Regular session Intuitive Surgical shares slipped roughly 0.2% to $524.65 on Friday, retreating from an early gain. The surgical-robot maker reported a fourth-quarter beat but tempered expectations with a 2026 outlook signaling slower growth in its core da Vinci procedures. Why this matters now: procedure growth—the count of operations performed with da Vinci and Ion systems—fuels recurring sales of instruments and accessories, making it the key metric investors focus on initially. Intuitive flagged a slowdown, forecasting global da Vinci procedure growth of around 13% to 15% in 2026, down from 18% in
23 January 2026
·····
1 2 3 … 6

Stock Market Today

  • SRG Global Shares Up 695% Over 5 Years Despite Recent 5.3% Decline
    February 6, 2026, 4:54 PM EST. SRG Global Limited (ASX:SRG) shares have surged 695% in total shareholder return over five years, including dividends, despite a recent 5.3% pullback last week amid a broader market drop. The stock's 529% price gain over five years reflects a shift from loss to profitability and steady 19% annual EPS growth in three years. However, the share price outpaced earnings per share (EPS) growth, rising 56% annually over the last three years, indicating elevated market enthusiasm. Analysts highlight the company's improved fundamentals, but investors remain watchful for upcoming revenue growth and market sentiment shifts.
Go toTop